Poor Linkage to Care Despite Significant Improvement in Access to Early cART in Central Poland – Data from Test and Keep in Care (TAK) Project - Fig 1

<p><b>a.</b> Kaplan-Meier plot for linked to care, stratified by year of HIV test <b>b.</b> Kaplan-Meier plot for starting cART by year of linked to care.</p

Additional baseline clinical characteristics for those who started cART.

<p>Additional baseline clinical characteristics for those who started cART.</p

Adjusted and unadjusted hazard ratios for started cART in those who are tested.

<p>Adjusted and unadjusted hazard ratios for started cART in those who are tested.</p

Baseline pre-clinical characteristics for those who were linked to care and for those who started cART.

<p>Baseline pre-clinical characteristics for those who were linked to care and for those who started cART.</p

Receiver operating characteristic curve for the ability of plasma hyaluronic acid to predict liver-related events.

<p>Receiver operating characteristic curve for the ability of plasma hyaluronic acid to predict liver-related events.</p

Distribution of plasma hyaluronic acid levels and any-liver related events during follow-up.

<p>Distribution of plasma hyaluronic acid levels and any-liver related events during follow-up.</p

Adjusted incidence rate ratios of any liver-related events.

<p>Note: The horizontal lines indicate 95% confidence intervals; HA: hyaluronic acid; HBsAg: hepatitis B surface antigen; HCVab: anti-HCV antibody; Group 1: HBsAg positive and/or anti-HCV/HCV-RNA positive; Group 2: anti-HCV positive/HCV-RNA negative.</p

Baseline characteristics of all patients and stratified according to hepatitis status.

<p>HBsAg: Hepatitis B surface antigen; HCV Ab: anti-HCV antibody; MSM: men who have sex with men; IDU: intravenous drug use; Het: heterosexual; S/A: south/Argentina; C: central; N: north; E: east; ARVs: antiretroviral drugs; ART: antiretroviral therapy; cART: combination antiretroviral therapy; HA: hyaluronic acid; IQR: interquartile range.</p

Incidence rate ratio (IRR) for all cause, AIDS and non-AIDS related mortality per calendar year of follow-up stratified by region.

<p>(Argentina was excluded from this analysis due to limited power). ^aadjusted for gender, age*, HIV exposure group, hepatitis B* and C* status, prior AIDS diagnosis, prior non-AIDS diagnosis, hypertension*, diabetes*, anaemia*, smoking status*, CD4 count*, baseline date* and on cART viral load*. ^badjusted for gender, age*, HIV exposure group, hepatitis B* and C* status, prior AIDS diagnosis, prior non-AIDS diagnosis, hypertension*, diabetes*, anaemia*, CD4 count*, baseline date* and on cART viral load*. *time-updated.</p

Results from univariate and multivariate Poisson regression analysis investigating mortality rates by region (South is the reference region).

a<p>adjusted for baseline variables gender, age, HIV exposure group, hepatitis B and C status, prior AIDS diagnosis, prior non-AIDS diagnosis, hypertension, diabetes, anaemia, smoking status, CD4 count, baseline date and on cART viral load.</p>b<p>adjusted as in a but age, hepatitis B and C status, hypertension, diabetes, anaemia, smoking status, CD4 count, year of follow-up and on cART viral load were included as time-updated covariates.</p>c<p>adjusted for baseline variables gender, age, HIV exposure group, hepatitis B and C status, prior AIDS diagnosis, prior non-AIDS diagnosis, hypertension, diabetes, anaemia, CD4 count, baseline date and on cART viral load.</p>d<p>adjusted as in a but age, hepatitis B and C status, hypertension, diabetes, anaemia, CD4 count, year of follow-up and on cART viral load were included as time-updated covariates.</p